New trials, publications, preprints and grants on this target, month by month.
Trial
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
30 Jun 2027· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)
31 Jan 2027· NA · NOT_YET_RECRUITING· CTGOV
Trial
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
1 Dec 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Advancing CLDN18.2-Targeted Therapies in Pancreatic Cancer: Current Clinical Development and Therapeutic Opportunities.
4 Nov 2026· Current treatment options in oncology· PUBMED
Publication
Claudin 18.2 as a specific diagnostic marker for pulmonary invasive mucinous adenocarcinoma.
4 Nov 2026· Pathology, research and practice· PUBMED
Publication
Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2-Expressing Gastric Cancer.
2 Nov 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics.
2 Nov 2026· Molecular pharmaceutics· PUBMED
Trial
Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma.
1 Nov 2026· Anticancer research· PUBMED
Publication
CLDN18.2-targeted CAR-NK cells suppress gastric cancer growth in preclinical models.
30 Oct 2026· Biochemical pharmacology· PUBMED
Publication
CLDN18.2 ADCs "A Real Step Forward" for Stomach Cancer.
27 Oct 2026· Cancer discovery· PUBMED
Publication
CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target.
22 Oct 2026· Frontiers in pharmacology· PUBMED
Publication
TRACE-CLDN: An Integrated Computational Pathology Framework for Tumor-Restricted Quantification of CLDN18.2 Expression Burden from H&E Whole-Slide Images in Intrahepatic Cholangiocarcinoma.
21 Oct 2026· Journal of imaging informatics in medicine· PUBMED
Publication
Claudin 18.2: from a tight junction protein to a breakthrough target in solid tumor immunotherapy.
21 Oct 2026· Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals· PUBMED
Publication
Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials.
8 Oct 2026· Investigational new drugs· PUBMED
Publication
ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer.
1 Oct 2026· Annals of surgical oncology· PUBMED
Publication
Retrospective Analysis of Zolbetuximab-Associated Hypoalbuminemia in Claudin 18.2-Positive Advanced Gastric Cancer.
1 Oct 2026· Cancer reports (Hoboken, N.J.)· PUBMED
Trial
Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
30 Sept 2026· EARLY_PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Repurposing Gastric Cancer Biomarkers for Mucinous Ovarian Carcinoma: ERBB2 and Claudin 18.2 as Therapeutic Targets.
28 Sept 2026· International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists· PUBMED
Publication
Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.
25 Sept 2026· Medical oncology (Northwood, London, England)· PUBMED
Publication
CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy.
25 Sept 2026· Frontiers in molecular medicine· PUBMED
Trial
QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ
24 Sept 2026· PHASE3 · RECRUITING· CTGOV
Publication
Correction: Deep learning prediction of MSI/dMMR, EBV, HER2, PD-L1, and CLDN18.2 status directly from hematoxylin and eosin-stained slides in gastric and gastroesophageal junction adenocarcinoma: a systematic review.
22 Sept 2026· Frontiers in oncology· PUBMED
Publication
CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoids.
18 Sept 2026· Biochemical and biophysical research communications· PUBMED
Publication
Retrospective analysis of Claudin 18.2 expression in 64 patients with advanced gastrointestinal peritoneal disease: a potential therapeutic target for high-grade appendiceal mucinous carcinoma.
18 Sept 2026· Journal of clinical pathology· PUBMED
Publication
Claudin 18.2 Expression and Outcomes in Resected Gallbladder and Biliary Tract Adenocarcinomas: A Pilot Clinicopathologic Study.
18 Sept 2026· International journal of surgical pathology· PUBMED
Trial
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
17 Sept 2026· PHASE3 · RECRUITING· CTGOV
Publication
Deep learning prediction of MSI/dMMR, EBV, HER2, PD-L1, and CLDN18.2 status directly from hematoxylin and eosin-stained slides in gastric and gastroesophageal junction adenocarcinoma: a systematic review.
9 Sept 2026· Frontiers in oncology· PUBMED
Publication
Spatial transcriptomics reveals club cell features and strong CLDN18 expression along the mucinous pathway to invasive mucinous adenocarcinoma.
8 Sept 2026· The Journal of pathology· PUBMED
Publication
Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.
7 Sept 2026· Gut· PUBMED